A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Biol Blood Marrow Transplant
; 17(7): 1033-42, 2011 Jul.
Article
em En
| MEDLINE
| ID: mdl-21074630
ABSTRACT
With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m², a substantial increase from the usual dose of 140 mg/m² in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Amifostina
/
Citoproteção
/
Linfoma
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article